In a type 2 diabetes patient with HbA1c 9.4% on linagliptin (Tradjenta) 5 mg daily and empagliflozin (Jardiance) 25 mg daily who refuses GLP‑1 receptor agonists and insulin, what is the appropriate next pharmacologic step?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 17, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Add a Sulfonylurea or Thiazolidinedione

Given your patient's refusal of GLP-1 receptor agonists and insulin, add a sulfonylurea (such as glimepiride) or pioglitazone to the current regimen of linagliptin and empagliflozin. With an A1c of 9.4%, this patient needs additional glucose-lowering efficacy beyond the current DPP-4 inhibitor and SGLT2 inhibitor combination.

Rationale for This Approach

The 2025 ADA Standards of Care 1 indicate that each oral agent class typically lowers A1c by 0.7-1.0% when added to existing therapy. Your patient is already on two complementary mechanisms (DPP-4 inhibitor and SGLT2 inhibitor), but remains 2.4% above the typical target of 7%. The combination of empagliflozin and linagliptin has demonstrated efficacy 2, but clearly requires intensification in this case.

Why Not Optimize Current Medications First?

  • Linagliptin is already at maximum dose (5 mg)
  • Empagliflozin is already at maximum dose (25 mg) for glycemic control 3
  • The current two-drug combination provides approximately 1.5-2.0% A1c reduction from baseline, insufficient for this patient's needs

Specific Medication Recommendations

Option 1: Add Sulfonylurea (Preferred for Cost)

  • Glimepiride 1-2 mg daily with breakfast
  • Titrate by 1-2 mg every 1-2 weeks based on fasting glucose
  • Maximum dose: 8 mg daily
  • Key advantage: Low cost, widely available 1
  • Critical caveat: Counsel extensively on hypoglycemia risk, especially with the SGLT2 inhibitor combination. Provide glucose tablets and glucagon prescription 1

Option 2: Add Pioglitazone

  • Pioglitazone 15-30 mg daily
  • Can increase to 45 mg if needed
  • Key advantage: No hypoglycemia risk, potential cardiovascular benefits 4
  • Critical caveats:
    • Avoid if history of heart failure (causes fluid retention)
    • Monitor for weight gain (2-3 kg expected)
    • Avoid in women with osteoporosis risk
    • Takes 8-12 weeks for full effect

Why This Patient Cannot Avoid Injectable Therapy Long-Term

The 2025 ADA guidelines 1 explicitly state that with A1c >10% or glucose ≥300 mg/dL, insulin should be considered regardless of patient preference. While your patient is at 9.4%, they are approaching this threshold. You must have a frank conversation now that if the A1c does not decrease to <8% within 3 months on triple oral therapy, insulin will become medically necessary.

The GLP-1 RA Discussion Should Be Revisited

The guidelines strongly recommend GLP-1 RAs over insulin 5, and they provide superior A1c reduction (1-2%) compared to oral agents 1. Explore the specific reasons for refusal:

  • If cost: Discuss patient assistance programs
  • If injection phobia: Explain once-weekly formulations and smaller needles than insulin
  • If gastrointestinal concerns: Explain slow titration protocols minimize nausea

Monitoring Plan

  • Recheck A1c in 3 months
  • If A1c remains >8%: Insulin becomes non-negotiable for preventing long-term complications
  • If A1c 7-8%: Continue current regimen with close monitoring
  • Monitor fasting glucose weekly if sulfonylurea added (hypoglycemia risk)

Common Pitfall to Avoid

Do not add a second DPP-4 inhibitor or combine with a GLP-1 RA - the patient is already on linagliptin. The guidelines explicitly state not to combine DPP-4 inhibitors with GLP-1 RAs as there is no additional benefit 1.

The empagliflozin should be continued for its cardiovascular and renal protective effects 1, 5, independent of glucose-lowering, assuming normal kidney function (eGFR >30 mL/min/1.73m²) 3.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.